Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 1,750 shares of the stock on the open market in a transaction dated Friday, July 11th. The stock was sold at an average price of $6.48, for a total value of $11,340.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Regulus Therapeutics (NASDAQ:RGLS) opened at 6.50 on Monday. Regulus Therapeutics has a 1-year low of $5.40 and a 1-year high of $12.42. The stock has a 50-day moving average of $7.32 and a 200-day moving average of $8.10. The company’s market cap is $281.8 million.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.16. Analysts expect that Regulus Therapeutics will post $-0.84 EPS for the current fiscal year.

A number of analysts have recently weighed in on RGLS shares. Analysts at Zacks upgraded shares of Regulus Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, June 17th. They now have a $7.80 price target on the stock. Finally, analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Regulus Therapeutics presently has an average rating of “Buy” and an average target price of $14.76.

Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.